ActiPatch® is FDA-cleared (510(k) K192234) for over-the-counter adjunctive treatment of musculoskeletal pain. These counts cover selected ActiPatch® clinical publications, not laboratory studies or studies of other devices. Study conditions and protocols differ, and individual results vary.
Published records
6
Each paper counted once
Randomized controlled trials
3
Library design label: RCT
Publication years
2012–2021
Earliest to latest record
What do clearance and research tell us?
FDA clearance identifies the device's permitted use; it is not an endorsement or a guarantee of results. These pain trials do not establish improved circulation, tissue repair, or reduced inflammation as ActiPatch® outcomes.
Individual experiences vary. Many people report noticing relief within a few hours; for some, it can take up to four days of consistent wear. Keep following the package directions and do not change medications or prescribed care without speaking with your healthcare provider.
RCT2016 · Rheumatology (Oxford)
Pulsed Electromagnetic Fields in Knee Osteoarthritis: A Double-Blind Placebo-Controlled Randomized Clinical Trial
Bagnato GL, Miceli G, Marino N, Sciortino D, Bagnato GF
In a four-week, randomized, double-blind, placebo-controlled ActiPatch® trial in knee osteoarthritis, 66 people were randomized and 60 completed the study. The investigators reported improvements in pain and physical function compared with placebo. Participants wore the device 12 hours a day.
Pulsed Radiofrequency Electromagnetic Field Therapy: A Potential Novel Treatment of Plantar Fasciitis
Brook J, Dauphinee DM, Korpinen J, Rawe IM
A seven-day, randomized, double-blind, placebo-controlled trial studied nightly use for plantar fasciitis. Among 70 participants who completed the study, the active-treatment group reported a greater reduction in morning pain than the placebo group.
Nerve pain is often described as burning, shooting, or tingling and can persist for months. ActiPatch® is FDA-cleared for adjunctive treatment of chronic musculoskeletal pain. Discuss adjunctive use with your clinician for nerve related pain conditions.
FDA-cleared adjunctive therapy. Always consult your clinician before starting any new therapy.
Frequently asked
Is PSWT therapy a substitute for prescribed nerve pain medication?
No. PSWT therapy is positioned as an adjunct to your existing care plan, not a replacement for medications prescribed by your clinician.
